A 72-year-old Japanese man presented with 43.1 × 109/l hairy cells and apparent splenomegaly. The leukemia cells had unevenly distributed microvilli and round nuclei with dense chromatin and one or two clear nucleoli, lacked CD25 expression and were negative for tartrate-resistant acid phosphatase. The case was diagnosed as hairy cell leukemia variant (HCLv) and proved refractory to various chemotherapies, including cladribine, pentostatin, interferon-α, CHOP and rituximab. Because of the CD52 expression, we treated the patient with alemtuzumab. Pretreatment with 22.5 Gy to the spleen reduced the spleen size from 12 to 4 cm below the left costal margin, and the number of circulating leukemic cells decreased from 229.0 to 63.6 × 109/l. Subsequent administration of 24.0 mg of alemtuzumab eliminated leukemic cells in the peripheral blood on day 12, and the spleen was not palpable after the administration of 54.0 mg of alemtuzumab. In vitro treatment with alemtuzumab confirmed the cytotoxic effect against the patient’s leukemic cells in the presence of complement. This is the first report showing clinical effectiveness of splenic irradiation and alemtuzumab against refractory HCLv.

Keywords:
Alemtuzumab, Hairy cell leukemia variant, Splenic irradiation
1.
Goodman GR, Bethel KJ, Saven A: Hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258–266.
2.
Mey U, Strehl J, Gorschlüter M, Ziske C, Glasmacher A, Pralle H, Schmidt-Wolf I: Advances in the treatment of hairy-cell leukemia. Lancet Oncol 2003;4:86–94.
3.
Sainati L, Matutes E, Mulligan S, de Oliveria MP, Rani S, Lampert IA, Catovsky D: A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990;76:157–162.
4.
Jaffe ES, Harris NL, Stein H, Vardiman JW: Hairy Cell Leukemia. World Health Organization of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 138–141.
5.
Matutes E, Wotherspoon A, Catovsky D: The variant form of hairy-cell leukemia. Best Pract Res Clin Haematol 2003;16:41–56.
6.
Robak T: Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365–376.
7.
Narat S, Gandla J, Doqan A, Mehta A: Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005;46:1229–1232.
8.
Quach H, Januszewicz H, Westerman D: Complete remission of hairy cell leukemia variant (HCl-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 2005;90(suppl):ECR26.
9.
Golay J, Manganini M, Rambaldi A, Introna M: Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476–1483.
10.
Golay J, Cortiana C, Manganini M, Cazzaniga G, Salvi A, Spinelli O, Bassan R, Barbui T, Biondi A, Rambaldi A, Introna M: The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica 2006;91:322–330.
11.
Quigley MM, Bethel KJ, Sharpe RW, Saven A: CD52 expression in hairy cell leukemia. Am J Hematol 2003;74:227–230.
12.
Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL: Heterogenous CD52 expression among hematologic neoplasms: implication for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174–7179.
13.
Fietz T, Rieger K, Schmittel A, Thiel E, Knauf W: Alemtuzumab (Campath-1H) in hairy cell leukemia relapsing after rituximab treatment. Hematol J 2004;5:451–452.
14.
Rebello P, Hale G: Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002;260:285–302.
15.
Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR: The CD45 tyrosine phosphate regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol 2000;12:505–516.
16.
Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA: Alemtuzumab (CAMPATH-1H) dose not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Lymphoma 2004;28:495–507.
17.
Thomas DA, O’Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM: Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906–3911.
18.
Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA: Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 2001;114:881–883.
19.
Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D: Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’s lymphoma: a retrospective review. Br J Haematol 2002;119:412–416.
20.
Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359–7368.
21.
Davis TA, Czerwinski DK, Levy R: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611–615.
22.
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3354–3361.
23.
Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, Hillmen P: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971–2979.
24.
Fraser G, Smith CA, Imrie K, Meyer R, the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care: Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007;14:96–109.
25.
Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K: Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia. Eur J Haematol 2007;78:545.
26.
Catovsky D, Richards S, Fooks J, Hamblin T: CLL trials in United Kingdom. The Medical Research Council CLL Trials 1,2,3. Leuk Lymphoma 1991;suppl 4:105–112.
27.
Sgarabotto D, Vianello F, Radossi P, Poletti A, Sotti G, Stefani PM, Sartori R, Girolami A: Remission in hairy cell leukemia-variant following splenic radiotherapy alone. Leuk Lymphoma 1997;26:395–398.
28.
Nishii K, Katayama N, Maeda H, Usui E, Takemitu T, Lorenzo FV, Nakase K, Shiku H: Successful treatment with low-dose splenic irradiation for massive splenomegaly in an elderly patient with hairy-cell leukemia. Eur J Haematol 2001;67:255–257.
29.
Williamson TS: Alemtuzumab. Clin J Oncol Nur 2001;5:287–288.
30.
Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, von Dongen JJ: Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990;136:1215–1222.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.